Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Completed · Phase 1/Phase 2

Conditions studied: Advanced Solid Malignancies

In brief

This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

Key facts

Study ID
NCT03363893
Run by
Carrick Therapeutics Limited
People needed
124
Starts
2017-11-14
Expected to finish
2022-12-15
Last updated by the study team
2026-06-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.